Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07655375
NA

Study Evaluating the Effect of UCB8600 on Mast Cell Activation in the Human Gut

Sponsor: Guy Boeckxstaens

View on ClinicalTrials.gov

Summary

Study evaluating the effect of UCB8600 on mast cell activation in the human gut: IBS is a disease characterized by abdominal pain and a change in stool. Treatment is limited to an adapted life style, dietary changes and medication to lessen cramps (spasmolytica), all of which have seen limited to no clinical success. Recently, we were able to demonstrate that mast cells play an active role in IBS symptoms. More specifically, they set histamine free when activated which heightens nerve sensitivity in the intestines which probably contributes to the abdominal pain. A new product called "UCB8600" is hypothesized to be able to counteract this by causing less mast cells to be activated. In this study we'll test this by administering UCB8600 on intestinal tissue and see if there is less mast cell activation. If the study produces good results, this new product could potentially be used as a treatment for IBS in the future.

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2026-06

Completion Date

2028-04

Last Updated

2026-06-17

Healthy Volunteers

Yes

Interventions

OTHER

Sample collection

Collection of colonic resection material (surgery patients) and rectal biopsies (IBS patients)

Locations (1)

University Hospitals Leuven

Leuven, Vlaams-Brabant, Belgium